Published in AIDS on June 19, 2014
Apparent spontaneous clearance of chronic hepatitis C virus infection in a HIV co-infected patient with decompensated cirrhosis: a case report. AIDS (2015) 0.75
Treatment optimization for HIV/HCV co-infected patients. Ther Adv Infect Dis (2016) 0.75
Spontaneous hepatitis C virus clearance in one HIV patient with chronic hepatitis C bearing IL28B-CC alleles and detectable plasma HIV-RNA. AIDS (2014) 0.75
The natural history of recent hepatitis C virus infection among blood donors and injection drug users in the country of Georgia. Virol J (2016) 0.75
Spontaneous clearance of hepatitis C virus during alcoholic hepatitis: the alcohol killed the virus? BMJ Case Rep (2015) 0.75
Estimating the Time to Diagnosis and the Chance of Spontaneous Clearance During Acute Hepatitis C in Human Immunodeficiency Virus-Infected Individuals. Open Forum Infect Dis (2017) 0.75
Prevalence of drug-resistant HIV-1 variants in untreated individuals in Europe: implications for clinical management. J Infect Dis (2005) 3.52
Pegylated IFN-alpha2b plus ribavirin as therapy for chronic hepatitis C in HIV-infected patients. AIDS (2003) 3.14
Hepatotoxicity of antiretroviral drugs is reduced after successful treatment of chronic hepatitis C in HIV-infected patients. J Infect Dis (2007) 2.40
[Therapeutic strategies in HIV infection]. Med Clin (Barc) (2005) 2.02
Natural pregnancies in HIV-serodiscordant couples receiving successful antiretroviral therapy. J Acquir Immune Defic Syndr (2006) 1.96
Rilpivirine: a next-generation non-nucleoside analogue for the treatment of HIV infection. Expert Opin Pharmacother (2012) 1.95
High sensitivity of specific genotypic tools for detection of X4 variants in antiretroviral-experienced patients suitable to be treated with CCR5 antagonists. J Antimicrob Chemother (2010) 1.94
Dried blood spots perform well in viral load monitoring of patients who receive antiretroviral treatment in rural Tanzania. Clin Infect Dis (2009) 1.92
[The Cohort of the Spanish HIV Research Network (CoRIS) and its associated biobank; organizational issues, main findings and losses to follow-up]. Enferm Infecc Microbiol Clin (2011) 1.92
Viral hepatitis and HIV co-infection. Antiviral Res (2009) 1.85
[Spanish cohort of naïve HIV-infected patients (CoRIS): rationale, organization and initial results]. Enferm Infecc Microbiol Clin (2007) 1.83
Predictors of kidney tubular dysfunction in HIV-infected patients treated with tenofovir: a pharmacogenetic study. Clin Infect Dis (2009) 1.81
Kidney tubular abnormalities in the absence of impaired glomerular function in HIV patients treated with tenofovir. AIDS (2009) 1.81
Evaluation of eight different bioinformatics tools to predict viral tropism in different human immunodeficiency virus type 1 subtypes. J Clin Microbiol (2008) 1.81
Impact of human immunodeficiency virus type 1 (HIV-1) genetic diversity on performance of four commercial viral load assays: LCx HIV RNA Quantitative, AMPLICOR HIV-1 MONITOR v1.5, VERSANT HIV-1 RNA 3.0, and NucliSens HIV-1 QT. J Clin Microbiol (2005) 1.75
Correlation between human immunodeficiency virus type 1 (HIV-1) RNA measurements obtained with dried blood spots and those obtained with plasma by use of Nuclisens EasyQ HIV-1 and Abbott RealTime HIV load tests. J Clin Microbiol (2009) 1.67
Influence of 516G>T polymorphisms at the gene encoding the CYP450-2B6 isoenzyme on efavirenz plasma concentrations in HIV-infected subjects. Clin Infect Dis (2005) 1.66
High concordance between HIV-1 drug resistance genotypes generated from plasma and dried blood spots in antiretroviral-experienced patients. AIDS (2007) 1.62
Tracing the HIV-1 subtype B mobility in Europe: a phylogeographic approach. Retrovirology (2009) 1.58
Switch from ritonavir-boosted to unboosted atazanavir guided by therapeutic drug monitoring. AIDS Res Hum Retroviruses (2008) 1.53
HIV-1 drug resistance genotyping from dried blood spots stored for 1 year at 4 degrees C. J Antimicrob Chemother (2008) 1.52
Paradoxical CD4+ T-cell decline in HIV-infected patients with complete virus suppression taking tenofovir and didanosine. AIDS (2005) 1.52
Genetic factors influencing atazanavir plasma concentrations and the risk of severe hyperbilirubinemia. AIDS (2007) 1.52
Severe liver disease associated with prolonged exposure to antiretroviral drugs. J Acquir Immune Defic Syndr (2006) 1.49
[Human immunodeficiency virus type 2 and human T-cell lymphotropic virus type 1 and type 2 infections in Spain: an update]. Enferm Infecc Microbiol Clin (2009) 1.43
Comparison of HIV-1 RNA measurements obtained by using plasma and dried blood spots in the automated abbott real-time viral load assay. J Clin Microbiol (2011) 1.42
HCV-specific T-cell responses in HIV/hepatitis C virus-coinfected patients on highly active antiretroviral therapy are comparable to those observed in hepatitis C virus-monoinfected individuals. J Acquir Immune Defic Syndr (2011) 1.42
[Spanish GESIDA/Nacional AIDS Plan Recommendations for antiretroviral therapy in HIV-infected Adults (October 2004)]. Enferm Infecc Microbiol Clin (2004) 1.42
Subtype variability, virological response and drug resistance assessed on dried blood spots collected from HIV patients on antiretroviral therapy in Angola. J Antimicrob Chemother (2008) 1.42
Antiretroviral drugs and liver injury. AIDS (2008) 1.40
The impact of transmitted drug resistance on the natural history of HIV infection and response to first-line therapy. AIDS (2006) 1.37
Plasma levels of atazanavir and the risk of hyperbilirubinemia are predicted by the 3435C-->T polymorphism at the multidrug resistance gene 1. Clin Infect Dis (2005) 1.33
Evaluation of performance across the dynamic range of the Abbott RealTime HIV-1 assay as compared to VERSANT HIV-1 RNA 3.0 and AMPLICOR HIV-1 MONITOR v1.5 using serial dilutions of 39 group M and O viruses. J Virol Methods (2006) 1.31
Management of chronic hepatitis B and C in HIV-coinfected patients. J Antimicrob Chemother (2006) 1.29
Prevalence of darunavir resistance mutations in HIV-1-infected patients failing other protease inhibitors. J Antimicrob Chemother (2007) 1.27
The calculated genetic barrier for antiretroviral drug resistance substitutions is largely similar for different HIV-1 subtypes. J Acquir Immune Defic Syndr (2006) 1.27
Role of weight-based ribavirin dosing and extended duration of therapy in chronic hepatitis C in HIV-infected patients: the PRESCO trial. AIDS Res Hum Retroviruses (2007) 1.26
Improvement in the determination of HIV-1 tropism using the V3 gene sequence and a combination of bioinformatic tools. J Med Virol (2009) 1.25
Is natural conception a valid option for HIV-serodiscordant couples? Hum Reprod (2007) 1.25
Impairment in kidney tubular function in patients receiving tenofovir is associated with higher tenofovir plasma concentrations. AIDS (2010) 1.24
Broad phenotypic cross-resistance to elvitegravir in HIV-infected patients failing on raltegravir-containing regimens. Antimicrob Agents Chemother (2012) 1.24
Directly acting antivirals against hepatitis C virus. J Antimicrob Chemother (2011) 1.22
Renal toxicity associated with tenofovir use. Expert Opin Drug Saf (2010) 1.21
Abnormal priming of CD4(+) T cells by dendritic cells expressing hepatitis C virus core and E1 proteins. J Virol (2002) 1.19
Genetic variants of ABCC10, a novel tenofovir transporter, are associated with kidney tubular dysfunction. J Infect Dis (2011) 1.18
Clinical and virological outcomes in HIV-infected patients with chronic hepatitis B on long-term nucleos(t)ide analogues. AIDS (2011) 1.16
Prevalence of transmitted HIV-1 drug resistance and the role of resistance algorithms: data from seroconverters in the CASCADE collaboration from 1987 to 2003. J Acquir Immune Defic Syndr (2005) 1.14
Low response to pegylated interferon plus ribavirin in HIV-infected patients with chronic hepatitis C treated with abacavir. Antivir Ther (2008) 1.14
Phylogenetic reconstruction of transmission events from individuals with acute HIV infection: toward more-rigorous epidemiological definitions. J Infect Dis (2009) 1.12
Antiretroviral-associated portal hypertension: a new clinical condition? Prevalence, predictors and outcome. Antivir Ther (2008) 1.12
Rilpivirine resistance mutations in HIV patients failing non-nucleoside reverse transcriptase inhibitor-based therapies. AIDS (2013) 1.10
Phenotypic impact of resistance mutations on etravirine susceptibility in HIV patients with prior failure to nonnucleoside analogues. AIDS (2008) 1.09
Baseline serum hepatitis C virus (HCV) RNA level and response at week 4 are the best predictors of relapse after treatment with pegylated interferon plus ribavirin in HIV/HCV-coinfected patients. J Acquir Immune Defic Syndr (2007) 1.08
Analyzing sleep abnormalities in HIV-infected patients treated with Efavirenz. Clin Infect Dis (2004) 1.07
Efficacy and safety of replacing lopinavir with atazanavir in HIV-infected patients with undetectable plasma viraemia: final results of the SLOAT trial. J Antimicrob Chemother (2007) 1.05
Evaluation of in-house genotyping assay performance using dried blood spot specimens in the Global World Health Organization laboratory network. Clin Infect Dis (2012) 1.05
Failure to detect human immunodeficiency virus type 1 superinfection in 28 HIV-seroconcordant individuals with high risk of reexposure to the virus. AIDS Res Hum Retroviruses (2004) 1.05
Efficacy of pegylated interferon plus ribavirin treatment in HIV/hepatitis C virus co-infected patients receiving abacavir plus lamivudine or tenofovir plus either lamivudine or emtricitabine as nucleoside analogue backbone. J Antimicrob Chemother (2008) 1.05
Episodes of low-level viral rebound in HIV-infected patients on antiretroviral therapy: frequency, predictors and outcome. J Antimicrob Chemother (2008) 1.05
Reductions in stavudine dose might ameliorate mitochondrial-associated complications without compromising antiviral activity. HIV Clin Trials (2005) 1.04
Decrease in serial prevalence of coinfection with hepatitis C virus among HIV-infected patients in Spain, 1997-2006. Clin Infect Dis (2009) 1.03
Pharmacogenetics of tenofovir treatment. Pharmacogenomics (2009) 1.03
Trends in the prescription of antiretroviral drugs and impact on plasma HIV-RNA measurements. J Antimicrob Chemother (2008) 1.03
Phylogeographical footprint of colonial history in the global dispersal of human immunodeficiency virus type 2 group A. J Gen Virol (2011) 1.03
Prevalence of etravirine (TMC-125) resistance mutations in HIV-infected patients with prior experience of non-nucleoside reverse transcriptase inhibitors. J Antimicrob Chemother (2007) 1.02
Emerging drugs for hepatitis C. Expert Opin Emerg Drugs (2008) 1.01
Hepatic safety profile of raltegravir in HIV-infected patients with chronic hepatitis C. J Antimicrob Chemother (2009) 1.01
Update on HIV/HCV coinfection. Curr HIV/AIDS Rep (2013) 1.00
Influence of liver fibrosis stage on plasma levels of antiretroviral drugs in HIV-infected patients with chronic hepatitis C. J Infect Dis (2007) 1.00
Noncirrhotic portal hypertension in HIV-infected patients: unique clinical and pathological findings. AIDS (2010) 0.99
Effectiveness and safety of simplification therapy with once-daily tenofovir, lamivudine, and efavirenz in HIV-1-infected patients with undetectable plasma viral load on HAART. HIV Clin Trials (2007) 0.99
Prevalence of natural polymorphisms at the HCV NS5A gene associated with resistance to daclatasvir, an NS5A inhibitor. Antivir Ther (2012) 0.99
Molecular and epidemiological characteristics of blood-borne virus infections among recent immigrants in Spain. J Med Virol (2006) 0.99
Changes in the human immunodeficiency virus p7-p1-p6 gag gene in drug-naive and pretreated patients. J Clin Microbiol (2003) 0.98
Prediction of response to pegylated interferon plus ribavirin in HIV/hepatitis C virus (HCV)-coinfected patients using HCV genotype, IL28B variations, and HCV-RNA load. J Hepatol (2011) 0.98
Minority HIV mutation detection in dried blood spots indicates high specimen integrity and reveals hidden archived drug resistance. J Clin Virol (2010) 0.98
Hepatitis C therapy with HCV NS5B polymerase inhibitors. Expert Opin Pharmacother (2013) 0.98
[Factors related to non-prescription of tuberculin skin testing in a cohort of HIV-infected people]. Enferm Infecc Microbiol Clin (2009) 0.98
Immunovirological response to triple nucleotide reverse-transcriptase inhibitors and ritonavir-boosted protease inhibitors in treatment-naive HIV-2-infected patients: The ACHIEV2E Collaboration Study Group. Clin Infect Dis (2011) 0.97
High prevalence of natural polymorphisms in Gag (CA-SP1) associated with reduced response to Bevirimat, an HIV-1 maturation inhibitor. AIDS (2010) 0.97
SENC (Spanish efavirenz vs. nevirapine comparison) trial: a randomized, open-label study in HIV-infected naive individuals. HIV Clin Trials (2002) 0.97
Safety and efficacy of tenofovir/emtricitabine plus nevirapine in HIV-infected patients. AIDS (2010) 0.96
Risk, predictors, and mortality associated with non-AIDS events in newly diagnosed HIV-infected patients: role of antiretroviral therapy. AIDS (2013) 0.96